结合的MIRACLE2和CAHP得分提高了STEMI患者在医院外心脏骤停时的死亡率预测
Katherine A Burns1, Saeid Mirzai1, Zachary D Pruitt1
1Department of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
JACC. Case reports
|November 14, 2025
概括
MIRACLE2和心脏骤停医院预后 (CAHP) 评分准确预测ST升高心肌梗塞 (OHCA-STEMI) 的医院外心脏骤停死亡率. 将这些分数结合起来,可以更好地识别高风险患者进行有针对性的干预.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 临床预后 临床预后
背景情况:
- 带有ST段升高心肌梗塞 (STEMI) 的非医院心脏骤停 (OHCA) 与高死亡率有关.
- 现有的预后分数,如MIRACLE2和心脏骤停医院预后 (CAHP) 已被验证为神经学结果,但它们对OHCA-STEMI患者医院死亡率预测的实用性尚不确定.
研究的目的:
- 评估和比较MIRACLE2和CAHP得分在预测OHCA-STEMI患者住院死亡率方面的表现.
- 为了确定这些分数是否可以指导临床决策关于穿皮冠状动脉干预和资源分配在这个高风险人群.
主要方法:
- 在2019年至2023年期间治疗的120名OHCA-STEMI患者的回顾性分析.
- 使用曲线下面面积 (AUC) 的MIRACLE2和CAHP分数的区分能力的比较.
- 用传统和衍生的切断值评估得分表现,考虑缺失数据的影响.
主要成果:
- 无论是MIRACLE2 (AUC 0.855) 还是CAHP (AUC 0.878) 都表现出了对死亡率预测的优秀歧视.
- 与MIRACLE2.2相比,CAHP由于缺少数据而更容易受到性能恶化的影响.
- 与传统的切断值相比,衍生切断值 (MIRACLE2 ≥4,CAHP ≥158) 显著提高了死亡率预测的灵敏度.
结论:
- MIRACLE2和CAHP得分是OHCA-STEMI患者住院死亡率的强有力的预测指标.
- 并行使用MIRACLE2和CAHP分数可以改善识别那些可能无法从皮肤穿透冠状动脉干预中受益的患者.
相关概念视频
Acute Coronary Syndrome I: Introduction
753
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
753
Acute Coronary Syndrome III: Diagnostic Studies
200
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
200
Cardiomyopathy III: Hypertrophic Cardiomyopathy
380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
Cardiopulmonary Resuscitation IV: Pharmacological Management
623
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
623
Cardiopulmonary Resuscitation III: AED Use
502
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
502
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
774
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
774


